M
M
Last name: MEYER
First name: Mickael
Email: Mickael.MEYER@univ-cotedazur.fr
Institution: UCA
Links
International audience
Initiating cell death in malignant cells through the activation of death receptors 4 and 5 (DR4/5) is a cancer therapeutic strategy re-entering a phase of intensive investigation due to recent advances that improved ligand activity, pharmacokinectics and lowered side effects (Wajant et al. Cancer Lett 2013). However, most drugs induce...
Cell response variability is a starting point in cancer drug resistance that has been difficult to analyze because the tolerant cell states are short lived. Here, we present fate-seq, an approach to isolate single cells in their transient states of drug sensitivity or tolerance before profiling. The drug response is predicted in live cells,...
Cell response variability is a starting point in cancer drug resistance that has been difficult to analyze because the tolerant cell states are short lived. Here, we present fate-seq, an approach to isolate single cells in their transient states of drug sensitivity or tolerance before profiling. The drug response is predicted in live cells,...
International audience
Highlights d Fate-seq links the drug response of a single cell to its own transcriptomic profile d Fate-seq recovers variable cell decision information from unstructured variability d It identifies molecular factors causing the intrinsic resistance to cancer drugs d A TRAIL therapeutic efficacy profile is performed in HeLa cells as proof of concept